IL132702A0 - Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors - Google Patents

Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors

Info

Publication number
IL132702A0
IL132702A0 IL13270298A IL13270298A IL132702A0 IL 132702 A0 IL132702 A0 IL 132702A0 IL 13270298 A IL13270298 A IL 13270298A IL 13270298 A IL13270298 A IL 13270298A IL 132702 A0 IL132702 A0 IL 132702A0
Authority
IL
Israel
Prior art keywords
testosterone
administration
drug delivery
delivery devices
precursors
Prior art date
Application number
IL13270298A
Other languages
English (en)
Original Assignee
Galen Chemicals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galen Chemicals Ltd filed Critical Galen Chemicals Ltd
Publication of IL132702A0 publication Critical patent/IL132702A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL13270298A 1997-05-07 1998-05-07 Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors IL132702A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE970333 1997-05-07
PCT/IE1998/000033 WO1998050016A2 (en) 1997-05-07 1998-05-07 Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors

Publications (1)

Publication Number Publication Date
IL132702A0 true IL132702A0 (en) 2001-03-19

Family

ID=11041465

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13270298A IL132702A0 (en) 1997-05-07 1998-05-07 Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors

Country Status (15)

Country Link
US (1) US6416780B1 (es)
EP (1) EP0981327B1 (es)
JP (1) JP2001524124A (es)
CN (1) CN1184957C (es)
AT (1) ATE227120T1 (es)
AU (1) AU741482B2 (es)
CA (1) CA2288046C (es)
DE (1) DE69809222T2 (es)
DK (1) DK0981327T3 (es)
ES (1) ES2187024T3 (es)
IL (1) IL132702A0 (es)
NO (1) NO995419L (es)
NZ (1) NZ501236A (es)
PT (1) PT981327E (es)
WO (1) WO1998050016A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
EP1494646B2 (en) * 2002-03-27 2017-10-04 Warner Chilcott (Ireland) Limited Intravaginal matrix drug delivery devices
US8404272B2 (en) 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
US8399013B2 (en) 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
EP3470108A1 (en) 2004-07-02 2019-04-17 Mati Therapeutics Inc. Treatment medium delivery device for delivery of treatment media to the eye
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
US8801694B2 (en) * 2005-08-11 2014-08-12 Massachusetts Institute Of Technology Intravesical drug delivery device
CN103393483B (zh) 2006-03-31 2016-08-24 玛提治疗有限公司 用于鼻泪系统的药物释放方法、结构及组合物
MX2009003876A (es) 2006-10-12 2009-05-11 Xenon Pharmaceuticals Inc Uso de compuestos de espiro-oxindol como agentes terapeuticos.
BRPI0820800B8 (pt) 2007-12-11 2021-06-22 Massachusetts Inst Technology dispositivo médico implantável para liberação controlada de droga
EA021615B1 (ru) 2008-02-04 2015-07-30 Тева Вимен'С Хелс, Инк. Цельное интравагинальное кольцо, содержащее прогестерон, и способ изготовления и применения такого кольца
US9034365B2 (en) 2008-05-20 2015-05-19 Poly-Med, Inc. Biostable, multipurpose, microbicidal intravaginal devices
JP5908279B2 (ja) * 2008-08-09 2016-04-26 マサチューセッツ インスチテュート オブ テクノロジーＭａｓｓａｃｈｕｓｅｔｔｓ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｔｅｃｈｎｏｌｏｇｙ 移植可能な薬物送達デバイス並びに男性の尿生殖器及び周囲組織を治療する方法
KR101286323B1 (ko) 2008-10-17 2013-07-15 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물 및 치료제로서의 그의 용도
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US20110269788A1 (en) 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
ES2401008T3 (es) 2009-06-26 2013-04-16 Taris Biomedical, Inc. Comprimidos farmacéuticos sólidos para dispositivos implantables para la administración de fármacos
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
MY165579A (en) 2009-10-14 2018-04-05 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
CN105726531A (zh) 2010-02-26 2016-07-06 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
ES2943334T3 (es) 2011-01-10 2023-06-12 Taris Biomedical Llc Régimen de lidocaína para el uso de tratamiento sostenido del dolor de vejiga y micción irritativa
BR112013019410A2 (pt) 2011-02-04 2019-09-24 Taris Biomedical Inc dispositivo implantável para liberação controlada de fármaco de solubilidade baixa
JP6100782B2 (ja) 2011-08-29 2017-03-22 キューエルティー インコーポレイテッド 緑内障および高眼圧症を治療するための活性剤の徐放送達
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
KR20140091022A (ko) 2011-10-31 2014-07-18 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
KR102398262B1 (ko) 2013-03-15 2022-05-13 타리스 바이오메디컬 엘엘씨 약물-투과성 구성요소를 가지는 약물 전달 장치 및 방법
WO2014144658A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Dual reactivity potent kunitz inhibitor of fibrinolysis
EP3736015B1 (en) 2013-08-19 2023-06-28 TARIS Biomedical LLC Multi-unit drug delivery devices
CN104546668B (zh) * 2013-10-23 2019-03-05 国家卫生计生委科学技术研究所 液体硅橡胶为载体的药物缓控释系统的制备及应用
JP6529583B2 (ja) * 2014-06-28 2019-06-12 ラボラトリオス アンドロマコ エス．エー．Ｌａｂｏｒａｔｏｒｉｏｓ Ａｎｄｒｏｍａｃｏ Ｓ．Ａ． 早産予防に有用な、長期間、持続し、継続した放出の黄体ホルモンを含む締結膣座剤
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
JP7425534B2 (ja) 2015-04-23 2024-01-31 タリス バイオメディカル エルエルシー 薬物透過性構成要素を有する薬物送達デバイス及び方法
KR20180129783A (ko) 2016-02-19 2018-12-05 피닉스 몰레큘라 디자인스 Ｒｓｋ 억제제로서 유용한 카르복사미드 유도체
CA3023465A1 (en) 2016-05-20 2017-11-23 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
BR112019011121A2 (pt) 2016-12-09 2019-10-01 Xenon Pharmaceuticals Inc compostos de benzenossulfonamida e seu uso como agentes terapêuticos
CA3103600A1 (en) 2018-06-13 2019-12-19 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
CR20210095A (es) 2018-07-27 2021-06-01 Xenon Pharmaceuticals Inc Metodo para tratar la epilepsia
EP3844158A1 (en) 2018-08-31 2021-07-07 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
CN112638879B (zh) 2018-08-31 2024-06-18 泽农医药公司 杂芳基取代的磺酰胺化合物及其作为治疗剂的用途
US11813354B1 (en) 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone
CN113677681A (zh) 2019-02-11 2021-11-19 凤凰分子设计公司 Rsk抑制剂的结晶形式
US20230203007A1 (en) 2021-09-24 2023-06-29 Xenon Pharmaceuticals Inc. Pyridinylacetamide derivatives as sodium channel activators
MX2024003646A (es) 2021-09-24 2024-05-28 Xenon Pharmaceuticals Inc Derivados de piridinilo como activadores del canal de sodio.
AU2022349462A1 (en) 2021-09-24 2024-04-11 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
US20240101531A1 (en) 2022-06-08 2024-03-28 Xenon Pharmaceuticals Inc. Pyridinamine derivatives and their use as potassium channel modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920805A (en) * 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
AU538961B2 (en) * 1980-06-09 1984-09-06 Alex Harvey Industries Limited Intra-vaginal device
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
IL116433A (en) * 1994-12-19 2002-02-10 Galen Chemicals Ltd INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS

Also Published As

Publication number Publication date
CN1255056A (zh) 2000-05-31
PT981327E (pt) 2003-02-28
CA2288046A1 (en) 1998-11-12
WO1998050016A2 (en) 1998-11-12
WO1998050016A3 (en) 1999-02-04
NZ501236A (en) 2002-02-01
DK0981327T3 (da) 2003-03-10
CA2288046C (en) 2006-10-03
DE69809222T2 (de) 2003-08-14
NO995419L (no) 2000-01-07
JP2001524124A (ja) 2001-11-27
AU7446998A (en) 1998-11-27
ES2187024T3 (es) 2003-05-16
NO995419D0 (no) 1999-11-05
US6416780B1 (en) 2002-07-09
ATE227120T1 (de) 2002-11-15
DE69809222D1 (de) 2002-12-12
AU741482B2 (en) 2001-11-29
EP0981327A2 (en) 2000-03-01
EP0981327B1 (en) 2002-11-06
CN1184957C (zh) 2005-01-19

Similar Documents

Publication Publication Date Title
IL132702A0 (en) Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
GB2341550A (en) Gastroretentive controlled release microspheres for improved drug delivery
AU1227899A (en) Osmotic medicament releasing system
NZ330145A (en) Drug delivery system, typically ring-shaped, for vaginal administration, with steroidal compounds dissolved in polymer core and with polymer skin
EP1504758A3 (en) Controlled-release formulations coated with aqueous dispersions of ethylcellulose
CA2432203A1 (en) Sustained release drug delivery devices with multiple agents
WO2003077972A8 (en) Implantable drug delivery system
AU4399196A (en) Intravaginal drug delivery devices for the administration of 17beta -oestradiol precursors
ZA97831B (en) Sustained delivery of an active agent using an implantable system.
HK1032010A1 (en) Medicament formulation with a controlled release of an active agent.
ES2192226T3 (es) Composicion farmaceutica oral que contiene agentes activos antimicrobianos y pantoprazol de liberacion prolongada.
ZA995839B (en) Orally administered controlled drug delivery system providing temporal and spatial control.
GR1002564B (el) Στερεα απο του στοματος χορηγουμενη φαρμακευτικη μορφη δοσιμετρησεως προγραμματισμενου ρυθμου απελευθερωσεως.
HK1043049A1 (en) Core tablet for controlled release of gliclazide after oral administration.
NZ515644A (en) Oil-core compositions for the sustained release of hydrophobic drugs
AU1495595A (en) Sustained-release dosage forms of alfuzosin hydrochloride
WO1998026767A3 (en) Site-specific controlled release dosage formulation for mesalamine
HRP20010684B1 (en) Directly compressible matrix for controlled release of single daily doses of clarithromycin
EP1106609A3 (en) Aminoalcohol derivative and medicament comprising the same
MX9803918A (es) Tabletas de liberacion rapida comprendiendo acido tolfenamico o una sal farmaceuticamente aceptable del mismo como ingrediente activo y un metodo para la preparacion de dicha tableta.
BG106342A (en) Low-dose tablets and preparation method
ZA9711660B (en) Therapeutic agent and treatment for canine intractable dermatitis.
AU1092095A (en) Intra-uterine ring for the release of an active agent, such as a hormone, and an introducer
AU5001699A (en) Chemical composition having spermicidal, bactericidal and virucidal activity andapparatus for delivery into the vaginal canal
PT8662T (pt) Doseador para distribuir um medicamento inoforo aplicado em especial para tratamento de animais

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired